Clinical trials: Phase I
Dry Eye Disease
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
The objective of this study is to assess safety and efficacy of DE-089 ophthalmic solution in patients with dry eye disease in Taiwan.
- Trial name
- NCT03216096
- Where
- 2 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Healthy
Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects
The purpose of this study is to determine how well tolerated and safe AZD5069 is at different dose levels in healthy male and/or females.
- Trial name
- NCT00953888
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
This phase I trial tests the safety, side effects, and best dose of camonsertib in combination with stereotactic body radiation therapy in controlling disease in patients with head and neck squamous cell cancer that has come back…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT07156227
- Testing
- Biospecimen Collection, Camonsertib, Computed Tomography
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Volunteers
A First-time-in-human Study of BGB149
This clinical trial is a Phase I, first-in-human. The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of BGB149 after single IV doses in healthy male and…
- Trial name
- NCT03795142
- Testing
- BGB149
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Primary Biliary Cholangitis
A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
Phase I Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
- Trial name
- NCT06888115
- Testing
- CS0159
- Where
- 3 sites in China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cascade Pharmaceuticals, Inc
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
The purpose of this study is to evaluate the use of IRX5183 in 1) patients with relapsed and/or refractory AML and 2) patients with high-risk MDS or chronic myelomonocytic leukemia (CMML).
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
- Trial name
- NCT02749708
- Testing
- IRX5183
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Radiation Therapy in Treating Women Undergoing Lumpectomy for Stage I or Stage IIA Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving intraoperative radiation therapy after lumpectomy followed by external-beam radiation therapy may kill any tumor cells that remain after surgery.
- Trial name
- NCT00602108
- Testing
- adjuvant therapy, conventional surgery, hypofractionated radiation therapy
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
mCRPC or Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
- Trial name
- NCT07533708
- Testing
- HLX3902
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Henlius Biotech
Upper Limb Spasticity Post-Stroke
Phase 1 Trial of JTM201 in Subjects With Post-stroke Upper Limb Spasticity
Phase 1 trial to evaluate the safety and efficacy of JTM201 compared with 'Botox® Inj.' in subjects with post-stroke upper limb spasticity
- Trial name
- NCT07292025
- Testing
- JTM201 in normal saline, BOTOX 100U in normal saline
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Jetema Co., Ltd.
Tennis Elbow
Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow
This study is testing a drug called TenoMiR that is being developed for the treatment of tennis elbow (lateral epicondylitis). The study drug is a new compound that works by improving the quality of the collagen which helps…
- Trial name
- NCT04670289
- Testing
- TenoMiR (Low Dose), TenoMiR (Medium Dose), TenoMiR (High Dose)
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Causeway Therapeutics
Diabetes Mellitus, Type 1
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants…
- Trial name
- NCT05184868
- Testing
- AT247, NovoLog, Fiasp
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arecor Limited
Health Adults, Asthma
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.
- Trial name
- NCT07900568
- Testing
- HXN-1013
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Kidney Cancer
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00589550
- Testing
- PEG-interferon alfa-2b, Sorafenib, gene expression analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Thomas Olencki
Advanced Solid Tumors
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
This is a single-arm, open-label, multi-center phase 1 clinical study designed to evaluate the safety and preliminary efficacy of NK042 cell injection in patients with advanced solid tumors.
- Trial name
- NKSOLID (NCT06773091)
- Testing
- NK042, Fludarabine (FLU), Cyclophosphamide (CTX)
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shanghai NK Cell Technology Co., LTD
Influenza, Human
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
This is a safety and Immunogenicity first-in-human dose-ranging study of self-amplifying RNA Seasonal Influenza Vaccine (ARCT-2138) in adults.
- Trial name
- NCT06125691
- Testing
- ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults
- Where
- 2 sites in Australia
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
Moderate or Severe Submental Fullness
A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation
The main purpose of this study is to evaluate the safety of HY-2003 in subjects with moderate to severe submental fat accumulation at different doses and dosing frequencies in comparison with the positive control and placebo.
- Trial name
- NCT06756490
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Neoplasm
Safety Study of Infusion of SGT-53 to Treat Solid Tumors
This is a Phase Ib study as a continuation of the original Phase I protocol. The purpose of this Phase Ib study is to evaluate the safety of a single course of SGT-53 in combination with docetaxel and determine the recommended…
- Trial name
- NCT00470613
- Testing
- SGT-53
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- SynerGene Therapeutics, Inc.
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well metformin hydrochloride works compared to placebo in treating patients with prostate cancer undergoing surgery. Metformin hydrochloride may make some enzymes active.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01433913
- Testing
- metformin hydrochloride, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Volunteers, Cancer Patients
Clinical Study of 68Ga-LNC1007 Injection PET/CT
This study is a single-arm, single-center trial aimed at evaluating the safety, pharmacokinetics, biodistribution and dosimetry of 68Ga-LNC1007 Injection in adult healthy volunteers and solid tumor patients.
- Trial name
- NCT06463782
- Testing
- 68Ga-LNC1007 Injection
- Where
- Singapore
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.